Beyond The Printed Page | September 1, 2016

The Backstory Behind What Hoos Hopes To Do At GSK

Source: Life Science Leader
Rob Wright author page

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

Cutting Room Floor

While at Bristol-Myers Squibb (BMS), Axel Hoos, M.D., Ph.D. brought ipilimumab (the pioneering CTL-4 immuno-oncology drug) to market, essentially launching the field of immuno-oncology. So, I was curious as to why he decided to join GSK, where he currently serves as SVP therapeutic area head for oncology R&D and head of immuno-oncology. But to understand Hoos’ (the subject of Life Science Leader magazine’s September 2016 feature article) path to GSK, you need to first know why he went to BMS in the first place.